Anti-ALK/ CD246/ NBLST3 monoclonal antibody

Anti-ALK/ CD246/ NBLST3 antibody for FACS & in-vivo assay

Target products collectionGo to ALK/ALK products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)


Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T56418-Ab-1/ GM-Tg-hg-T56418-Ab-2Anti-Human ALK monoclonal antibodyHuman
GM-Tg-rg-T56418-Ab-1/ GM-Tg-rg-T56418-Ab-2Anti-Rat ALK monoclonal antibodyRat
GM-Tg-mg-T56418-Ab-1/ GM-Tg-mg-T56418-Ab-2Anti-Mouse ALK monoclonal antibodyMouse
GM-Tg-cynog-T56418-Ab-1/ GM-Tg-cynog-T56418-Ab-2Anti-Cynomolgus/ Rhesus macaque ALK monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T56418-Ab-1/ GM-Tg-felg-T56418-Ab-2Anti-Feline ALK monoclonal antibodyFeline
GM-Tg-cang-T56418-Ab-1/ GM-Tg-cang-T56418-Ab-2Anti-Canine ALK monoclonal antibodyCanine
GM-Tg-bovg-T56418-Ab-1/ GM-Tg-bovg-T56418-Ab-2Anti-Bovine ALK monoclonal antibodyBovine
GM-Tg-equg-T56418-Ab-1/ GM-Tg-equg-T56418-Ab-2Anti-Equine ALK monoclonal antibodyEquine

Size: 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T56418-Ab-1/ GM-Tg-hg-T56418-Ab-2; GM-Tg-rg-T56418-Ab-1/ GM-Tg-rg-T56418-Ab-2;
GM-Tg-mg-T56418-Ab-1/ GM-Tg-mg-T56418-Ab-2; GM-Tg-cynog-T56418-Ab-1/ GM-Tg-cynog-T56418-Ab-2;
GM-Tg-felg-T56418-Ab-1/ GM-Tg-felg-T56418-Ab-2; GM-Tg-cang-T56418-Ab-1/ GM-Tg-cang-T56418-Ab-2;
GM-Tg-bovg-T56418-Ab-1/ GM-Tg-bovg-T56418-Ab-2; GM-Tg-equg-T56418-Ab-1/ GM-Tg-equg-T56418-Ab-2
Products NameAnti-ALK monoclonal antibody
Formatmab
Target NameALK
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)
IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-ALK benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species ALK/ CD246/ NBLST3 VLP (virus-like particle) (Products Developing)
    ORF Viral VectorpGMAD000452house mouse Alk Adenovirus plasmid
    ORF Viral VectorvGMAD000452house mouse Alk Adenovirus particle


    Target information

    Target IDGM-T56418
    Target NameALK
    Gene ID238,11682,266802,704823,483021,101091689,536642
    Gene Symbol and SynonymsALK,ALK1,CD246,NBLST3,Tcrz
    Uniprot AccessionQ9UM73,P0DV84
    Uniprot Entry NameALK_HUMAN,-
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target, Immuno-oncology Target
    DiseaseNon-Small Cell Lung Cancer, Anaplastic large cell carcinoma (ALCL), Anaplastic Large Cell Lymphoma (ALCL)
    Gene EnsemblENSG00000171094
    Target ClassificationCheckpoint-Immuno Oncology, Kinase

    The target: ALK, gene name: ALK, also named as CD246, NBLST3. This gene encodes a receptor tyrosine kinase, which belongs to the insulin receptor superfamily. This protein comprises an extracellular domain, an hydrophobic stretch corresponding to a single pass transmembrane region, and an intracellular kinase domain. It plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system. This gene has been found to be rearranged, mutated, or amplified in a series of tumours including anaplastic large cell lymphomas, neuroblastoma, and non-small cell lung cancer. The chromosomal rearrangements are the most common genetic alterations in this gene, which result in creation of multiple fusion genes in tumourigenesis, including ALK (chromosome 2)/EML4 (chromosome 2), ALK/RANBP2 (chromosome 2), ALK/ATIC (chromosome 2), ALK/TFG (chromosome 3), ALK/NPM1 (chromosome 5), ALK/SQS™1 (chromosome 5), ALK/KIF5B (chromosome 10), ALK/CLTC (chromosome 17), ALK/TPM4 (chromosome 19), and ALK/MSN (chromosome X).[provided by RefSeq, Jan 2011].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.